Pan-genomic analyses of 47 complete genomes of the<i>Rickettsia</i>genus and prediction of new vaccine targets and virulence factors of the species

Felice, Andrei Giacchetto; Alves, Leandro Gomes; Freitas, Alissa S F; Rodrigues, Thaís Cristina Vilela; Jaiswal, Arun Kumar; Tiwari, Sandeep; Gomes, Lucas Gabriel Rodrigues; Miranda, Fábio; Ramos, Rommel Thiago Jucá; Azevedo, Vasco; Oliveira, Lívia Costa de; Oliveira, Carlo José; Soares, Siomar de Castro; Benevides, Leandro de Jesus

doi:10.1080/07391102.2021.1898473

Cited by 2 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antigenic drug targets were further analyzed to predict vaccine candidates (Sah et al, 2020). Similar studies were performed using PBIT to screen pathogen proteomes of Serratia marcescens (Prado et al, 2022), Pseudomonas aeruginosa (Rahman et al, 2023;Atron, 2023), Salmonella enterica serovar Typhimurium (Kocabaş et al, 2022), Rickettsia (Felice et al, 2022), Corynebacterium ulcerans, Corynebacterium silvaticum (Cerqueira et al, 2022) to identify potential drug and vaccine targets. In addition to high-throughput analysis, individual proteins, such as MEP2 protein in Candida albicans (Khalil, 2020), have also been assessed for their safety through the non-homology modules of PBIT. )…”

Section: Role In Drug and Vaccine Target Identificationmentioning

confidence: 99%

See 1 more Smart Citation

PBIT_V3: A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates

Chakraborty,

Askari,

Barai

et al. 2024

Protein Science

View full text Add to dashboard Cite

Rise of life‐threatening superbugs, pandemics and epidemics warrants the need for cost‐effective and novel pharmacological interventions. Availability of publicly available proteomes of pathogens supports development of high‐throughput discovery platforms to prioritize potential drug‐targets and develop testable hypothesis for pharmacological screening. The pipeline builder for identification of target (PBIT) was developed in 2016 and updated in 2021, with the purpose of accelerating the search for drug‐targets by integration of methods like comparative and subtractive genomics, essentiality/virulence and druggability analysis. Since then, it has been used for identification of drugs and vaccine targets, safety profiling of multiepitope vaccines and mRNA vaccine construction against a broad‐spectrum of pathogens. This tool has now been updated with functionalities related to systems biology and immuno‐informatics and validated by analysing 48 putative antigens of Mycobacterium tuberculosis documented in literature. PBITv3 available as both online and offline tools will enhance drug discovery against emerging drug‐resistant infectious agents. PBITv3 can be freely accessed at http://pbit3.bicnirrh.res.in/offline.php.This article is protected by copyright. All rights reserved.

show abstract

Section: Role In Drug and Vaccine Target Identificationmentioning

confidence: 99%

“…iii. Drug and vaccine targets were predicted from Bordetella pertussis and analyzed for essentiality and nonhomology to gut microbiota using PBIT (Felice et al, 2022). iv.…”

Section: Role In Drug and Vaccine Target Identificationmentioning

confidence: 99%

PBIT_V3: A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates

Chakraborty,

Askari,

Barai

et al. 2024

Protein Science

View full text Add to dashboard Cite

show abstract

“…Researchers found 90–100% homology among the four Rickettsia groups. In addition, eight protein types were also identified in this research to support polyvalent vaccine development against Rickettsia , while nine candidates were identified as drug targets [ 135 ]. Although the study predicted that polyvalent vaccines would interact with the majority of microorganisms in this vast group, potentially leading to a vaccine, predictive data must also be supported with in vivo and in vitro data.…”

Section: Pan-genomics Analysis or Comparative Genomicsmentioning

confidence: 99%

Recent Advances in Genomics-Based Approaches for the Development of Intracellular Bacterial Pathogen Vaccines

et al. 2022

View full text Add to dashboard Cite

Infectious diseases continue to be a leading cause of morbidity and mortality worldwide. The majority of infectious diseases are caused by intracellular pathogenic bacteria (IPB). Historically, conventional vaccination drives have helped control the pathogenesis of intracellular bacteria and the emergence of antimicrobial resistance, saving millions of lives. However, in light of various limitations, many diseases that involve IPB still do not have adequate vaccines. In response to increasing demand for novel vaccine development strategies, a new area of vaccine research emerged following the advent of genomics technology, which changed the paradigm of vaccine development by utilizing the complete genomic data of microorganisms against them. It became possible to identify genes related to disease virulence, genetic patterns linked to disease virulence, as well as the genetic components that supported immunity and favorable vaccine responses. Complete genomic databases, and advancements in transcriptomics, metabolomics, structural genomics, proteomics, immunomics, pan-genomics, synthetic genomics, and population biology have allowed researchers to identify potential vaccine candidates and predict their effects in patients. New vaccines have been created against diseases for which previously there were no vaccines available, and existing vaccines have been improved. This review highlights the key issues and explores the evolution of vaccines. The increasing volume of IPB genomic data, and their application in novel genome-based techniques for vaccine development, were also examined, along with their characteristics, and the opportunities and obstacles involved. Critically, the application of genomics technology has helped researchers rapidly select and evaluate candidate antigens. Novel vaccines capable of addressing the limitations associated with conventional vaccines have been developed and pressing healthcare issues are being addressed.

show abstract

Pan-genomic analyses of 47 complete genomes of theRickettsiagenus and prediction of new vaccine targets and virulence factors of the species

Cited by 2 publications

References 48 publications

PBIT_V3: A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates

PBIT_V3: A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates

Recent Advances in Genomics-Based Approaches for the Development of Intracellular Bacterial Pathogen Vaccines

Contact Info

Product

Resources

About

Pan-genomic analyses of 47 complete genomes of theRickettsiagenus and prediction of new vaccine targets and virulence factors of the species

Cited by 2 publications

References 48 publications

PBITV3: A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates

PBITV3: A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates

Recent Advances in Genomics-Based Approaches for the Development of Intracellular Bacterial Pathogen Vaccines

Contact Info

Product

Resources

About

PBIT_V3: A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates

PBIT_V3: A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates